Berger Montague PC has filed a class action lawsuit against ADMA Biologics and reminds investors who purchased ADMA common stock between August 9, 2024 and March 25, 2026 that they have until August 10, 2026 to seek lead plaintiff appointment. The suit alleges ADMA engaged in a channel-stuffing scheme to inflate revenue growth amid declining demand for its flagship product ASCENIV and failed to disclose related party transactions. A March 24, 2026 Culper Research report claimed that without the alleged scheme, ADMA would have seen a 3 percent revenue decline in 2025 instead of the reported 20 percent growth. Following the report, ADMA shares fell 16 percent on March 24 and an additional 15 percent on March 25, closing at $9.63 per share.
ADMA Biologics IncClass action lawsuit alleges channel-stuffing and undisclosed related-party transactions, leading to share decline.
